viewAnteris Technologies Ltd

Admedus secures strategic cornerstone investor from Hong Kong

The deal secures equity funding, a new loan facility and a gateway to the China market.

toy blocks that spell the word FUNDING
The new arrangements are part of the company's recapitalisation strategy

Admedus Ltd (ASX:AHZ) continues to build its relationship with strategic investor and shareholder Star Bright Holding Ltd, who will increase its holding to 19.99%.

Star Bright has agreed to subscribe for up to an additional 68.9 million shares in Admedus as part of a share placement raising up to $7.7 million.

Admedus has also entered into a $5 million unsecured loan facility with Star Bright for the purposes of repaying the existing, higher interest loan from Partners For Growth.

READ: Admedus extends successful distribution deal for medication delivery pumps

Admedus’s CEO Wayne Paterson said: “Having already indicated a commitment to provide $18 million of long-term funding to our Immunotherapies business, and having participated in the last capital raise, Star Bright have demonstrated their belief and interest in our company.

“Madam Zhang, and her company, are aligned with our mission to deliver clinically superior solutions to patients and we welcome a significant strategic investor onto our register.”

A gateway to China

Star Bright is a Hong Kong-based private investment company 100% owned by Madam Zhang Lishan whose business interests are primarily global asset and equity investments,

Star Bright recognises the potential of Admedus’ ADAPT technology to deliver tangible benefits for the global medical community and its ability to improve the lives and health outcomes of patients.

As well as their equity investment, Star Bright has indicated their interest in helping to establish an Admedus commercial base in China in the near term.

Star Bright’s shares will be issued in two tranches

The first tranche of 42.59 million shares priced at 10 cents raising $4.25 million was issued on 22 August 2018.

The second tranche of 26.28 million shares will be priced at 13.03 cents will raise an addition $3.42 million and is yet to be issued.

Notably, Star Bright has agreed not to sell the placement shares for 12 months from their issue date.

Beneficial loan facility terms

The new Star Bright $5 million unsecured loan facility has a three year term on a 5% annual coupon payable quarterly with the potential for shares to be issued in lieu of the coupon payment.

The previous loan facility has now been repaid and had a much higher interest rate of 11.75%.

Quick facts: Anteris Technologies Ltd

Price: 5.18 AUD

Market: ASX
Market Cap: $30.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...



Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read